Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse-Deterrent Oxycodone Product ELI-201
03 déc. 2014 09h55 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Dec. 3, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today successful results from a pivotal bioequivalence (BE) study for...